ABOUT THE RESEARCHER

OVERVIEW

Dr. Fahey's research involves the application of SPECT and PET in pediatrics, the use of limited angle tomography in radiology and nuclear medicine and quantification in small animal imaging. His research goals include: Optimizating the application of PET in pediatrics. Developing more accurate dosimetric models in pediatric nuclear medicine. Improving reconstruction techniques for limited angle tomography. Improving quantitative techniques in small animal nuclear imaging. About Frederic Fahey Dr. Fahey received his DSc degree from Harvard School of Public Health. He is currently the 2012-2013 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He has also been awarded Fellow status by the American College of Radiology (ACR).

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Impact of reconstruction parameters on lesion detection and localization in joint ictal/inter-ictal SPECT reconstruction. Ann Nucl Med. 2021 Sep 24. View abstract
  2. PET/computed tomography in inpatients: part 1, international survey. Nucl Med Commun. 2021 Sep 01; 42(9):1045-1051. View abstract
  3. Renal 99mTc-DMSA pharmacokinetics in pediatric patients. EJNMMI Phys. 2021 Jul 20; 8(1):53. View abstract
  4. Detecting lumbar lesions in 99m Tc-MDP SPECT by deep learning: Comparison with physicians. Med Phys. 2021 Aug; 48(8):4249-4261. View abstract
  5. Residency training for diagnostic imaging physicists should be expanded to include nuclear medicine physics. Med Phys. 2021 Aug; 48(8):4123-4126. View abstract
  6. Response to Febo-Rodriguez et al. Am J Gastroenterol. 2021 07 01; 116(7):1553. View abstract
  7. Developing and implementing a multi-modality imaging optimization study in paediatric radiology: Experience and recommendations from an IAEA coordinated research project. Phys Med. 2021 Feb; 82:255-265. View abstract
  8. DeepAMO: a multi-slice, multi-view anthropomorphic model observer for visual detection tasks performed on volume images. J Med Imaging (Bellingham). 2021 Jul; 8(4):041204. View abstract
  9. Celebrating eighty years of radionuclide therapy and the work of Saul Hertz. J Appl Clin Med Phys. 2021 Jan; 22(1):4-10. View abstract
  10. Dosimetric considerations of 99mTc-MDP uptake within the epiphyseal plates of the long bones of pediatric patients. Phys Med Biol. 2020 12 02; 65(23):235025. View abstract
  11. Body morphometry appropriate computational phantoms for dose and risk optimization in pediatric renal imaging with Tc-99m DMSA and Tc-99m MAG3. Phys Med Biol. 2020 11 27; 65(23):235026. View abstract
  12. Pediatric Solid Gastric Emptying Scintigraphy: Normative Value Guidelines and Nonstandard Meal Alternatives. Am J Gastroenterol. 2020 11; 115(11):1830-1839. View abstract
  13. Developing and Implementing an Imaging Optimization Study in Pediatric Nuclear Medicine: Experience and Recommendations from an IAEA-Coordinated Research Project. J Nucl Med. 2021 04; 62(4):570-576. View abstract
  14. Pediatric Solid Gastric Emptying Scintigraphy: Normative Value Guidelines and Nonstandard Meal Alternatives. Am J Gastroenterol. 2020 Aug 19. View abstract
  15. Ethical aspects in the use of radiation in medicine: update from ICRP Task Group 109. Ann ICRP. 2020 Dec; 49(1_suppl):143-153. View abstract
  16. Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. J Nucl Med. 2021 03; 62(3):422-430. View abstract
  17. Paediatric nuclear medicine practice: an international survey by the IAEA. Eur J Nucl Med Mol Imaging. 2020 06; 47(6):1552-1563. View abstract
  18. Current pediatric administered activity guidelines for 99m Tc-DMSA SPECT based on patient weight do not provide the same task-based image quality. Med Phys. 2019 Nov; 46(11):4847-4856. View abstract
  19. Update: Image Gently and Nuclear Medicine at 10 Years. J Nucl Med. 2019 Apr; 60(4):7N-9N. View abstract
  20. Dose Optimization of Hybrid Imaging. Health Phys. 2019 Feb; 116(2):179-183. View abstract
  21. Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network. J Nucl Med. 2019 05; 60(5):677-682. View abstract
  22. Re-evaluation of pediatric 18F-FDG dosimetry: Cristy-Eckerman versus UF/NCI hybrid computational phantoms. Phys Med Biol. 2018 08 14; 63(16):165012. View abstract
  23. Establishing a Radiation Safety Credential for Nuclear Medicine Technologists. J Nucl Med Technol. 2018 Dec; 46(4):391-393. View abstract
  24. A projection image database to investigate factors affecting image quality in weight-based dosing: application to pediatric renal SPECT. Phys Med Biol. 2018 07 09; 63(14):145004. View abstract
  25. Standardization of Administered Activities in Pediatric Nuclear Medicine. J Am Coll Radiol. 2018 04; 15(4):695-696. View abstract
  26. Use of Monte Carlo Techniques in Nuclear Medicine. J Am Coll Radiol. 2018 03; 15(3 Pt A):446-448. View abstract
  27. How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting. Cancer Imaging. 2017 Nov 07; 17(1):28. View abstract
  28. Appropriate Use of Effective Dose in Radiation Protection and Risk Assessment. Health Phys. 2017 08; 113(2):102-109. View abstract
  29. Lassmann Recognized with Loevinger-Berman Award. J Nucl Med. 2017 08; 58(8):14N. View abstract
  30. Operational and Dosimetric Aspects of Pediatric PET/CT. J Nucl Med. 2017 09; 58(9):1360-1366. View abstract
  31. Stomach frame-count-based attenuation correction of dynamic posterior view gastric emptying scintigraphy with continuous acquisition in children. Pediatr Radiol. 2017 Nov; 47(12):1599-1607. View abstract
  32. Appropriate Use Criteria for Ventilation-Perfusion Imaging in Pulmonary Embolism: Summary and Excerpts. J Nucl Med. 2017 05; 58(5):13N-15N. View abstract
  33. Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys. 2017 Dec; 4(1):15. View abstract
  34. Joint reconstruction of Ictal/inter-ictal SPECT data for improved epileptic foci localization. Med Phys. 2017 Apr; 44(4):1437-1444. View abstract
  35. Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2017 08; 58(8):1264-1269. View abstract
  36. History Corner: Archive Project and History Fund. J Nucl Med. 2017 01; 58(1):19N. View abstract
  37. 2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. J Nucl Med. 2016 12; 57(12):15N-18N. View abstract
  38. Dose Estimation in Pediatric Nuclear Medicine. Semin Nucl Med. 2017 03; 47(2):118-125. View abstract
  39. Targeted Radionuclide Therapy: Practical Applications and Future Prospects. Biomark Cancer. 2016; 8(Suppl 2):35-8. View abstract
  40. Administered Activities in Pediatric Nuclear Medicine and the Impact of the 2010 North American Consensus Guidelines on General Hospitals in the United States. J Nucl Med. 2016 09; 57(9):1478-85. View abstract
  41. Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2-Current Standards and the Path Toward Global Standardization. J Nucl Med. 2016 Jul; 57(7):1148-57. View abstract
  42. Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds. EJNMMI Res. 2016 Dec; 6(1):28. View abstract
  43. The Current State of Nuclear Medicine Physics Training: Findings of the AAPM/SNMMI Task Force. J Nucl Med. 2016 07; 57(7):1146-7. View abstract
  44. A risk index for pediatric patients undergoing diagnostic imaging with (99m)Tc-dimercaptosuccinic acid that accounts for body habitus. Phys Med Biol. 2016 Mar 21; 61(6):2319-32. View abstract
  45. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med. 2016 Jan; 57(1):151-62. View abstract
  46. Role of Reference Levels in Nuclear Medicine: A Report of the SNMMI Dose Optimization Task Force. J Nucl Med. 2015 Dec; 56(12):1960-4. View abstract
  47. AAPM/SNMMI Joint Task Force: report on the current state of nuclear medicine physics training. J Appl Clin Med Phys. 2015 09 08; 16(5):3-13. View abstract
  48. Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation. 2015 Sep; 99(9):e132-9. View abstract
  49. AAPM/SNMMI Joint Task Force: report on the current state of nuclear medicine physics training. J Appl Clin Med Phys. 2015 Sep; 16(5):3-13. View abstract
  50. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45. View abstract
  51. (18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines. Nucl Med Biol. 2015 Oct; 42(10):796-803. View abstract
  52. MO-DE-201-03. Med Phys. 2015 Jun; 42(6):3559. View abstract
  53. Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy. J Nucl Med. 2015 Jul; 56(7):1119-29. View abstract
  54. Effects of Image Gently and the North American guidelines: administered activities in children at 13 North American pediatric hospitals. J Nucl Med. 2015 Jun; 56(6):962-7. View abstract
  55. History Corner: from the new SNMMI historian. J Nucl Med. 2015 Apr; 56(4):11N. View abstract
  56. Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resources. J Nucl Med. 2015 Apr; 56(4):646-51. View abstract
  57. Radiation doses for pediatric nuclear medicine studies: comparing the North American consensus guidelines and the pediatric dosage card of the European Association of Nuclear Medicine. Pediatr Radiol. 2015 Apr; 45(5):706-13. View abstract
  58. Beyond current guidelines: reduction in minimum administered radiopharmaceutical activity with preserved diagnostic image quality in pediatric hepatobiliary scintigraphy. Eur J Nucl Med Mol Imaging. 2014 Dec; 41(12):2346-53. View abstract
  59. 18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium. J Nucl Med. 2014 Sep; 55(9):1473-80. View abstract
  60. In any use of ionizing radiation,consideration of the benefits of the exposures to possible risks is a central concern, for the physician and patient. Semin Nucl Med. 2014 May; 44(3):160-1. View abstract
  61. Dose optimization in nuclear medicine. Semin Nucl Med. 2014 May; 44(3):193-201. View abstract
  62. Pediatric nuclear medicine and radiation dose. Semin Nucl Med. 2014 May; 44(3):202-9. View abstract
  63. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Med. 2014 Feb; 55(2):337-48. View abstract
  64. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014 Jan; 16(2):310-7. View abstract
  65. Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer. Nucl Med Biol. 2013 Nov; 40(8):1043-8. View abstract
  66. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. Clin Nucl Med. 2013 Aug; 38(8):604-7. View abstract
  67. Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2013 Aug; 54(8):1237-43. View abstract
  68. WE-E-137-01: RSO Refresher Training. Med Phys. 2013 Jun; 40(6Part29):487. View abstract
  69. WE-C-144-01: The Management of Imaging Procedure Dose 2: Nuclear Medicine. Med Phys. 2013 Jun; 40(6Part29):486. View abstract
  70. Specific uptake of 99mTc-NC100692, an avß3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol. 2013 Aug; 40(6):788-94. View abstract
  71. Effect of the prosthetic group on the pharmacologic properties of 18F-labeled rhodamine B, a potential myocardial perfusion agent for positron emission tomography (PET). J Med Chem. 2012 Dec 27; 55(24):11004-12. View abstract
  72. Promoting radiation dose optimization. J Nucl Med. 2012 Sep; 53(9):33N. View abstract
  73. Gastric emptying in children: what is the best acquisition method? J Pediatr Gastroenterol Nutr. 2012 Aug; 55(2):191-3. View abstract
  74. SNM leadership update: ensuring the health of our profession. J Nucl Med. 2012 Jul; 53(7):22N. View abstract
  75. Proposed name change for the society of nuclear medicine. J Nucl Med. 2012 May; 53(5):11N. View abstract
  76. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol. 2012 Jul; 108(3):469-75. View abstract
  77. The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke. Nat Neurosci. 2012 Mar 04; 15(4):565-73. View abstract
  78. Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med Technol. 2012 Mar; 40(1):13-24. View abstract
  79. Strengthening our profession through community and collaboration. J Nucl Med. 2012 Feb; 53(2):14N. View abstract
  80. Reduction in radiation dose in mercaptoacetyltriglycerine renography with enhanced planar processing. Radiology. 2011 Dec; 261(3):907-15. View abstract
  81. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. Semin Nucl Med. 2011 Sep; 41(5):354-63. View abstract
  82. Economic and radiation costs of initial imaging approaches after a child's first febrile urinary tract infection. Clin Pediatr (Phila). 2012 Jan; 51(1):23-30. View abstract
  83. Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med. 2011 Aug; 52(8):1240-51. View abstract
  84. Nuclear medicine in the first year of life. J Nucl Med. 2011 Jun; 52(6):905-25. View abstract
  85. Improved quality of pediatric 123I-MIBG images with medium-energy collimators. J Nucl Med Technol. 2011 Jun; 39(2):100-4. View abstract
  86. Identifying ureteropelvic junction obstruction by fluorescence imaging: a comparative study of imaging modalities to assess renal function and degree of obstruction in a mouse model. J Urol. 2011 Jun; 185(6):2405-13. View abstract
  87. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2011 Feb; 52(2):188-95. View abstract
  88. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol. 2011 Jan; 38(1):29-38. View abstract
  89. Costs and consequences of universal sibling screening for vesicoureteral reflux: decision analysis. Pediatrics. 2010 Nov; 126(5):865-71. View abstract
  90. Pediatric 99mTc-MDP bone SPECT with ordered subset expectation maximization iterative reconstruction with isotropic 3D resolution recovery. Radiology. 2010 Dec; 257(3):793-801. View abstract
  91. Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody. Inflamm Bowel Dis. 2010 Sep; 16(9):1458-66. View abstract
  92. Estimated cumulative radiation dose from PET/CT in children with malignancies. Pediatr Radiol. 2010 Oct; 40(10):1712-3; author reply 1714-5. View abstract
  93. Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis. Am J Pathol. 2010 Sep; 177(3):1459-69. View abstract
  94. Variability in PET quantitation within a multicenter consortium. Med Phys. 2010 Jul; 37(7):3660-6. View abstract
  95. Seasonal variation in the effect of constant ambient temperature of 24 degrees C in reducing FDG uptake by brown adipose tissue in children. Eur J Nucl Med Mol Imaging. 2010 Oct; 37(10):1854-60. View abstract
  96. Cheese is a reliable alternative meal for solid-phase gastric emptying study. Nucl Med Commun. 2010 May; 31(5):430-3. View abstract
  97. Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent. Nucl Med Biol. 2010 Apr; 37(3):365-70. View abstract
  98. Use of (99m)Tc-MDP SPECT for assessment of mandibular growth: development of normal values. Eur J Nucl Med Mol Imaging. 2010 May; 37(5):1002-10. View abstract
  99. Synthesis of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent. Appl Radiat Isot. 2010 Jan; 68(1):96-100. View abstract
  100. Dosimetry of Pediatric PET/CT. J Nucl Med. 2009 Sep; 50(9):1483-91. View abstract
  101. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009 Jul 09; 460(7252):259-63. View abstract
  102. Pediatric 99mTc-DMSA SPECT performed by using iterative reconstruction with isotropic resolution recovery: improved image quality and reduced radiopharmaceutical activity. Radiology. 2009 May; 251(2):511-6. View abstract
  103. Constant ambient temperature of 24 degrees C significantly reduces FDG uptake by brown adipose tissue in children scanned during the winter. Eur J Nucl Med Mol Imaging. 2009 Apr; 36(4):602-6. View abstract
  104. Pediatric radiation exposure and effective dose reduction during voiding cystourethrography. Radiology. 2008 Dec; 249(3):1002-9. View abstract
  105. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008 Jun 15; 22(12):1662-76. View abstract
  106. Administered radiopharmaceutical doses in children: a survey of 13 pediatric hospitals in North America. J Nucl Med. 2008 Jun; 49(6):1024-7. View abstract
  107. Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC). Eur J Nucl Med Mol Imaging. 2008 Sep; 35(9):1651-8. View abstract
  108. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008 Jan; 49(1):68-78. View abstract
  109. PET and PET/CT in pediatric oncology. Semin Nucl Med. 2007 Sep; 37(5):316-31. View abstract
  110. Early experience with fluorine-18 sodium fluoride bone PET in young patients with back pain. J Pediatr Orthop. 2007 Apr-May; 27(3):277-82. View abstract
  111. The Neuroimaging Center of the Pediatric Brain Tumor Consortium-collaborative neuroimaging in pediatric brain tumor research: a work in progress. AJNR Am J Neuroradiol. 2007 Apr; 28(4):603-7. View abstract
  112. Dosimetry and adequacy of CT-based attenuation correction for pediatric PET: phantom study. Radiology. 2007 Apr; 243(1):96-104. View abstract
  113. Evaluation of the quantitative capability of a high-resolution positron emission tomography scanner for small animal imaging. J Comput Assist Tomogr. 2004 Nov-Dec; 28(6):842-8. View abstract
  114. Standardization and quantification of radionuclide solid gastric-emptying studies. J Nucl Med. 2004 May; 45(5):760-4. View abstract
  115. Instrumentation in positron emission tomography. Neuroimaging Clin N Am. 2003 Nov; 13(4):659-69. View abstract
  116. Application of TACT to the evaluation of total joint arthroplasty. Med Phys. 2003 Mar; 30(3):454-60. View abstract
  117. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg. 2002 Oct; 95(4):1052-9, table of contents. View abstract
  118. Angular disparity in ETACT scintimammography. Med Phys. 2002 Sep; 29(9):1980-3. View abstract
  119. Data acquisition in PET imaging. J Nucl Med Technol. 2002 Jun; 30(2):39-49. View abstract
  120. Positron emission tomography instrumentation. Radiol Clin North Am. 2001 Sep; 39(5):919-29. View abstract
  121. Reduced regional and global cerebral blood flow during fenoldopam-induced hypotension in volunteers. Anesth Analg. 2001 Jul; 93(1):45-52. View abstract
  122. Emission tuned-aperture computed tomography: a novel approach to scintimammography. J Nucl Med. 2001 Jul; 42(7):1121-7. View abstract
  123. Cortical activity related to accuracy of letter recognition. Neuroimage. 2000 Feb; 11(2):111-23. View abstract
  124. Evaluation of brain activity in FDG PET studies. J Comput Assist Tomogr. 1998 Nov-Dec; 22(6):953-61. View abstract
  125. Lag phase quantification for solid gastric emptying studies. J Nucl Med. 1996 Oct; 37(10):1639-43. View abstract
  126. Intermodality, retrospective image registration in the thorax. J Nucl Med. 1995 Dec; 36(12):2333-8. View abstract
  127. Quantitation of SPECT performance: Report of Task Group 4, Nuclear Medicine Committee. Med Phys. 1995 Apr; 22(4):401-9. View abstract
  128. Evaluation of emission-transmission registration in thoracic PET. J Nucl Med. 1994 Nov; 35(11):1777-80. View abstract
  129. Sensitivity, resolution and image quality with a multi-head SPECT camera. J Nucl Med. 1992 Oct; 33(10):1859-63. View abstract
  130. Biphasic solid and liquid gastric emptying in normal controls and diabetics using continuous acquisition in LAO view. Dig Dis Sci. 1992 May; 37(5):744-50. View abstract
  131. Calculation of a gallbladder ejection fraction: advantage of continuous sincalide infusion over the three-minute infusion method. J Nucl Med. 1992 Apr; 33(4):537-41. View abstract
  132. 3-D SPECT simulations of a complex 3-D mathematical brain model: effects of 3-D geometric detector response, attenuation, scatter, and statistical noise. IEEE Trans Med Imaging. 1992; 11(2):176-86. View abstract
  133. Improved detection of small cavernous hemangiomas of the liver with high-resolution three-headed SPECT. J Nucl Med. 1991 Nov; 32(11):2086-91. View abstract
  134. Three-dimensional SPECT simulations of a complex three-dimensional mathematical brain model and measurements of the three-dimensional physical brain phantom. J Nucl Med. 1991 Oct; 32(10):1923-30. View abstract
  135. Digital image processing of radiation therapy portal films. Comput Med Imaging Graph. 1989 May-Jun; 13(3):227-33. View abstract
  136. Left anterior oblique projection and peak-to-scatter ratio for attenuation compensation of gastric emptying studies. J Nucl Med. 1989 Feb; 30(2):233-9. View abstract
  137. Characterization of the rotating display. Invest Radiol. 1988 Sep; 23(9):692-4. View abstract
  138. Renal scans in pregnant transplant patients. J Nucl Med. 1988 Aug; 29(8):1364-7. View abstract
  139. The effect of the Garren-Edwards Gastric Bubble on solid and liquid gastric emptying. Clin Nucl Med. 1988 Aug; 13(8):586-9. View abstract
  140. Comparison of bone mineral density in both hips. Radiology. 1988 Apr; 167(1):151-3. View abstract
  141. Hepatic visualization on iodine-131 whole-body thyroid cancer scans. J Nucl Med. 1987 Sep; 28(9):1408-11. View abstract
  142. 99mTc-glucoheptonate for quantitation of differential renal function. AJR Am J Roentgenol. 1987 May; 148(5):889-93. View abstract
  143. Detection efficiency of a high-pressure gas scintillation proportional chamber. Med Phys. 1987 Jan-Feb; 14(1):115-23. View abstract
  144. Impact of radiocontaminants in commercially available iodine-123: dosimetric evaluation. J Nucl Med. 1986 Mar; 27(3):428-32. View abstract
  145. Energy resolution in a high-pressure gas scintillation proportional chamber. Med Phys. 1986 Jan-Feb; 13(1):25-34. View abstract
  146. Thallium/technetium functional imaging of the thyroid and parathyroid. A case report. Clin Nucl Med. 1985 Dec; 10(12):865-7. View abstract
  147. The feasibility of epidemiologic studies of cancer in residents near the Rocky Flats Plant. Health Phys. 1982 Jan; 42(1):65-8. View abstract
  148. Choosing populations to study the health effects of low-dose ionizing radiation. Am J Public Health. 1981 Nov; 71(11):1247-52. View abstract